STEMI
Conditions
Interventions
experimental group:Recombinant Human Prourokinase intravenous injection
control group:Heparin intravenous injection
Sponsors
Tianjin Chest Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Male and female, aged 18 to 75 years; 2) Symptoms < 12 hours, with thrombolytic indications, excluding thrombolytic contraindications ST-segment elevation myocardial infarction patients; 3) Willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients who have undergone intravenous thrombolysis in patients with PCI; 2) History of intracranial hemorrhage; 3) Ischemic stroke within 3 months; 4) Suspected aortic dissection; 5) Active bleeding or bleeding factors (including menstruation); 6) Severe head and face damage within 3 months; 7) Severe or not well controlled hypertension (SBP> 180mmHg or DBP> 110mmHg); 8) 3 weeks of severe trauma or major surgery or can not oppress the bleeding; 9) Patients with malignant tumors; 10) Combined with severe liver and kidney dysfunction; 11) Pregnant women, lactating women or women who may be pregnant; 12) Known to study drug or contrast agent allergies or contraindications; 13) Patients after coronary artery bypass grafting; 14) Patients also participate in other clinical studies.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Postoperative ECG ST segment fall range;cTNT and CK-MB peaks;LVEF and serum NT-proBNP levels were measered at 1 day and 30 days after operation;major cardiovascular events (MACE); | — |
Primary
| Measure | Time frame |
|---|---|
| immediate coronary flow;cTFC myocardial perfusion after PCI;MBG Myocardial perfusion after PCI; | — |
Countries
China
Contacts
Public ContactLi Chunjie, Fu Xianghua, Huo Yong.
Tianjin Chest Hospital
Outcome results
None listed